tiprankstipranks
Trending News
More News >

Autolus Therapeutics Announces Leadership Transition in Finance

Story Highlights
Autolus Therapeutics Announces Leadership Transition in Finance

Confident Investing Starts Here:

Autolus Therapeutics ( (AUTL) ) has shared an announcement.

On February 24, 2025, Autolus Therapeutics announced the resignation of Andrew Mercieca, Vice President of Finance and principal accounting officer, effective August 2025. His departure is amicable and not due to any disagreements with the company. On April 3, 2025, the Board appointed Rob Dolski, the current CFO, as the new principal accounting officer, consolidating his roles without additional compensation, indicating a seamless transition in leadership.

More about Autolus Therapeutics

Autolus Therapeutics operates in the biotechnology industry, focusing on the development of advanced therapies for the treatment of cancer.

YTD Price Performance: -40.30%

Average Trading Volume: 1,254,064

Technical Sentiment Signal: Strong Buy

Current Market Cap: $375.2M

See more insights into AUTL stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App